| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -1.5 | -4.4 |
| Net income | -1.5 | -4.4 |
| EPS (diluted, $ a share) | $-0.03 | $-0.45 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NYSE: TOVX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Theriva Biologics, Inc.: key numbers
- Share price
- $0.1400Close, Nov 17
- Market cap
- $6.42M
- Shares outstanding
- 45.89MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Theriva Biologics, Inc.
All →Theriva Biologics Financial Results
Theriva Biologics reported third quarter 2026 financial results, highlighting a cash position of $8.5 million and a runway into Q1 2027. The company also noted the completion of the sale of its SYN-004 portfolio to Biossil Labs for $350,000 upfront and up to $91 million in milestones.
“We are pleased with the clinical progress achieved this quarter. Patient enrollment and dosing in the VIRAGE2 trial is progressing well, and we anticipate completing enrollment by the end of the fourth quarter of this year.”
Steven A. Shallcross, Chief Executive Officer of Theriva Biologics
“The recently signed asset sale agreement for SYN-004 (ribaxamase) and the related portfolio of antibiotic-degrading enzymes to Biossil Labs Inc. demonstrates our commitment to deriving value from our legacy microbiome programs while continuing to focus on the development of our lead program VCN-01.”
Steven A. Shallcross, Chief Executive Officer of Theriva Biologics
Theriva Biologics Divestiture to Biossil Labs Inc.
Theriva Biologics completed the sale of its antibiotic-degrading enzyme portfolio, including SYN-004 (ribaxamase), to Biossil Labs Inc. for an upfront payment of $350,000. Theriva is eligible for up to $91 million in regulatory and sales milestones plus royalties, while Biossil assumes all future development costs and responsibilities.
- Counterparty
- Biossil Labs Inc.